PMID- 31367639
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220409
IS  - 2319-9644 (Print)
IS  - 2279-042X (Electronic)
IS  - 2279-042X (Linking)
VI  - 8
IP  - 2
DP  - 2019 Apr-Jun
TI  - Outcome Evaluation of a Subcutaneous Immunoglobulin Clinical Management Program.
PG  - 52-63
LID - 10.4103/jrpp.JRPP_18_36 [doi]
AB  - OBJECTIVE: The aim of this study is to compare clinical and cost outcomes of 
      patients undergoing subcutaneous immunoglobulin (SCIG) therapy who were managed 
      by a clinical management program to the matched controls in the United States. 
      METHODS: This was a retrospective cohort study using administrative claims data 
      from the PharMetrics Plus (PMTX+) database. The patients from a high-touch SCIG 
      clinical management program were matched to nonprogram patients in PMTX+ database 
      using 1:4 propensity score matching without replacement. All patients were 
      followed for 1 year during the study from September 1, 2011, to June 30, 2014, 
      and both clinical and cost outcomes were compared between the two cohorts using 
      the generalized estimating equation model. FINDINGS: The clinical outcomes were 
      measured by infection- and infusion-related adverse events (AEs). Most of them 
      were not significantly different (P > 0.05) between the intervention group and 
      matched controls. Although the proportion of patients who had a mild less common 
      AE was higher (4.4% vs. 0.0%;P = 0.04), it could be due to increased reporting 
      among the intervention group. The annual adjusted mean total health-care costs of 
      patients in the program (n = 45) were $20,868 lower compared to matched controls 
      (n = 180), representing a 24% lower costs ($66,450 vs. $87,318;P = 0.009). 
      CONCLUSION: This study may demonstrate that clinical management programs for SCIG 
      may be associated with lower health-care costs and comparable infection and 
      severe AE rates. The limitations of this study included a small sample size and a 
      reliance on administrative claim data.
FAU - Zhu, Julia
AU  - Zhu J
AD  - Health Analytics, Research and Reporting, Walgreen Co., Deerfield, IL, USA.
FAU - Ayer, Gretchen
AU  - Ayer G
AD  - Business Development, Option Care Inc., Bannockburn, IL, USA.
FAU - Kirkham, Heather S
AU  - Kirkham HS
AD  - Health Analytics, Research and Reporting, Walgreen Co., Deerfield, IL, USA.
FAU - Chen, Chi-Chang
AU  - Chen CC
AD  - Health Economics and Outcomes Research, IQVIA, Plymouth Meeting, PA, USA.
FAU - Wade, Rolin L
AU  - Wade RL
AD  - Health Economics and Outcomes Research, IQVIA, Plymouth Meeting, PA, USA.
FAU - Karkare, Swapna U
AU  - Karkare SU
AD  - Health Economics and Outcomes Research, IQVIA, Deerfield, IL, USA.
FAU - Robson, Chester H
AU  - Robson CH
AD  - Office of Clinical Integrity, Walgreen Co., Deerfield, IL, USA.
FAU - Orange, Jordan S
AU  - Orange JS
AD  - Baylor College of Medicine, Houston, TX, USA.
AD  - Texas Children's Hospital, Houston, TX, USA.
LA  - eng
PT  - Journal Article
PL  - India
TA  - J Res Pharm Pract
JT  - Journal of research in pharmacy practice
JID - 101614023
PMC - PMC6636416
OTO - NOTNLM
OT  - Clinical outcomes
OT  - cost outcomes
OT  - home infusion
OT  - specialty pharmacy
OT  - subcutaneous Immunoglobulin
COIS- Julia Zhu, Heather S. Kirkham, and Chester H. Robson were a full-time employee of 
      the study sponsor, Walgreen Co. during the conduct of the study. Gretchen Ayer is 
      a salaried employee of the study sponsor, Option Care Enterprises. Chi-Chang 
      Chen, Rolin L. Wade, and Swapna Karkare reported grants from Walgreens during the 
      conduct of the study. Dr. Jordan S. Orange reports personal fees from Walgreen 
      Co./Option Care Inc., during the conduct of the study; grants and personal fees 
      from CSL Behring, personal fees from Baxalta, from Grifols, personal fees from 
      ASD Healthcare, personal fees from ADMA Biologics, non-financial support from 
      BPL, and personal fees from Atlantic Research Group, outside the submitted work.
EDAT- 2019/08/02 06:00
MHDA- 2019/08/02 06:01
PMCR- 2019/04/01
CRDT- 2019/08/02 06:00
PHST- 2019/08/02 06:00 [entrez]
PHST- 2019/08/02 06:00 [pubmed]
PHST- 2019/08/02 06:01 [medline]
PHST- 2019/04/01 00:00 [pmc-release]
AID - JRPP-8-52 [pii]
AID - 10.4103/jrpp.JRPP_18_36 [doi]
PST - ppublish
SO  - J Res Pharm Pract. 2019 Apr-Jun;8(2):52-63. doi: 10.4103/jrpp.JRPP_18_36.